Fox Run Management, L.L.C. Repligen Corp Transaction History

Fox Run Management, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$120.0 - $182.95 $361,560 - $551,228	3,013 Added 73.74%	7,099 $894,000
Q1 2024 May 13, 2024	BUY	$170.78 - $208.42 $697,807 - $851,604	4,086 New	4,086 $751,000
Q2 2023 Aug 11, 2023	BUY	$138.42 - $180.31 $87,204 - $113,595	630 Added 10.11%	6,862 $970,000
Q1 2023 May 12, 2023	BUY	$154.26 - $198.1 $961,348 - $1.23 Million	6,232 New	6,232 $1.05 Million
Q4 2020 Feb 08, 2021	SELL	$148.08 - $206.57 $254,549 - $355,093	-1,719 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$122.51 - $158.27 $210,594 - $272,066	1,719 New	1,719 $254,000
Q4 2019 Feb 14, 2020	SELL	$73.84 - $93.08 $248,176 - $312,841	-3,361 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$76.65 - $95.51 $257,620 - $321,009	3,361 New	3,361 $258,000
Q1 2019 Oct 17, 2019	SELL	$49.45 - $62.8 $427,841 - $543,345	-8,652 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$48.26 - $68.88 $417,545 - $595,949	8,652 New	8,652 $456,000

488

54.2M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.02B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.